During the quantitative analysis of membrane ACE2 by flow cytometry, no decrease in expression of this molecule was observed on PBMCs and populations of T-cells, B-cells and CD16+ monocytic/dendritic cells from COVID-19 patients. This evidence concerns the gene ACE2 and COVID-19.